ReviewTurkish journal of ophthalmology2017
Corticosteroid Treatment in Diabetic Macular Edema.
Review in Turkish journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Ultra-Early OCT Changes After Intravitreal Injection: Evidence Consistent with Transient Mechanical Compression.Vision (Basel, Switzerland) · 2026Article
- Intravitreal faricimab in patients with refractory diabetic macular edema: 6-month fluid analysis using artificial intelligence.BMC ophthalmology · 2026Observational
- Real-World Evidence of the Long-Term Effectiveness of 0.2 μg/Day Fluocinolone Acetonide Implant in Persistent and Recurrent Diabetic Macular Edema - A Single Center Study.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Comparison of the Effects of Phacoemulsıfıcatıon and Dexamethasone Implantation in the Same Session with Other Phakic Conditions.Beyoglu eye journal · 2023Article
- Ocular safety of intravitreal ethylene diamine tetra acetic acid (EDTA): An experimental feasibility study.Toxicology reports · 2023Article
- Risk factor analysis and clinical decision tree model construction for diabetic retinopathy in Western China.World journal of diabetes · 2022Article
- The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers.International journal of molecular sciences · 2022Review
- The Correlation Between MicroRNAs and Diabetic Retinopathy.Frontiers in immunology · 2022Review
- Diabetic macular edema: Safe and effective treatment with intravitreal triamcinolone acetonide (Taioftal).PloS one · 2021Article
- A New Approach for Diabetic Macular Edema Treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes.Current ophthalmology reports · 2020Article
- Assessment of single nucleotide polymorphisms associated with steroid-induced ocular hypertension.International journal of ophthalmology · 2020Article
- Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized EyesTurkish journal of ophthalmology · 2019Article
- Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic macular edema is the most common cause of visual impairment in patients with diabetes mellitus. The pathogenesis of macular edema is complex and multifactorial. For many years, laser photocoagulation has been considered the standard therapy for the treatment of diabetic macular edema; however, few patients achieve significant improvements in visual acuity. Today the intravitreal administration of anti-inflammatory or anti-angiogenic agents together with the use of laser photocoagulation represents the standard of care for the treatment of this complication. The intravitreal route of administration minimizes the systemic side effects of corticosteroids. Steroid-related ocular side effects are elevated intraocular pressure and cataract, while injection-related complications include endophthalmitis, vitreous hemorrhage, and retinal detachment. In order to reduce the risks and complications, intravitreal implants have been developed recently to provide sustained release of corticosteroids and reduce repeated injections for the management of diabetic macular edema. In this review, the efficacy, safety, and therapeutic potential of intravitreal corticosteroids in diabetic macular edema are discussed with a review of recent literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.